-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

ASH Poster Walk on Clinical Trials in Progress: Live Q&A

PhD Trainee
Program: ASH Poster Walks
Thursday, December 10, 2020: 7:00 AM-8:00 AM
Moderator:
Disclosures:
No relevant conflicts of interest to declare.
Panelists:
Alan E. Mast, MD, PhD, Blood Center of Wisconsin , Grzegorz S. Nowakowski, MD, Mayo Clinic , Richard F. Little, MD, MPH, National Cancer Institute , Jeffrey I. Weitz, MD, FRCPC, McMaster University , Andrew C Perkins, PhD, Icon Cancer Care , John Pasi, MB, ChB, PhD, FRCP, FRCPath, FRCPCH, Royal London Haemophilia Centre, Barts and the London School of Medicine and Dentistry , Kenneth W. Wood, PhD, Forma Therapeutics, Inc. , Nichola Cooper, MD, MRCP, Hammersmith Hospital , Meghan C. Thompson, MD, CLL Program, Memorial Sloan Kettering Cancer Center and Gail J. Roboz, MD, Weill Medical College of Cornell University New York-Presbyterian Hospital
Disclosures:
No relevant conflicts of interest to declare.
The following abstracts will be featured during this session:

Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis, Andrew Perkins

First-in-Human Phase 1/2 Clinical Trial of SIG-001, an Innovative Shielded Cell Therapy Platform, for Hemophilia Α, Pasi 

An Adaptive, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE), Kenneth Wood

Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study, Nichola Coper

Phase 1 and Dose Expansion Study of APR-246 in Combination with Ibrutinib or Venetoclax-Based Therapy in Subjects with TP53-Mutant Relapsed and/or Refractory Non-Hodgkin Lymphomas (NHL) Including Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL), Meghan Thompson

Ameli-01: Phase I, Open Label Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), Administered in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Gail Roboz

See more of: ASH Poster Walks
<< Previous Session | Next Session >>